相关实验视频
Updated: Jan 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
909
人工智能和自然语言处理患者的叙述,以评估减肥的塞马格卢提德
Akshaya Srikanth Bhagavathula1
1Department of Public Health, College of Health and Human Sciences, North Dakota State University, Fargo, ND 58108, USA.
Annals of epidemiology
|September 16, 2025
概括
人工智能和自然语言处理分析了患者对西马格卢提德用于体重管理的评论. 患者报告60天后平均体重减轻32.2磅,常见的副作用包括恶心和头痛.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 医疗保健中的人工智能
- 患者报告的结果
背景情况:
- 塞马格卢提德越来越多地用于体重管理.
- 了解现实世界的有效性和安全性至关重要.
- 患者评论为治疗经验提供了宝贵的见解.
研究的目的:
- 用AI和NLP分析患者对塞马格卢提德的评论.
- 评估塞马格卢提德在体重管理中的实际有效性.
- 为了确定与塞马格卢提德相关的常见副作用和用户体验.
主要方法:
- 从Drugs.com (2021年7月至2025年3月) 获得的772份塞马格卢提德评价的回顾性分析.
- 使用基于变压器的BERT模型进行情绪分析.
- 主题建模 (LDA,LSA) 和集群分析以确定主题和用户配置文件.
主要成果:
- 服用塞马格卢提德>60天的用户报告平均体重减轻32.2磅.
- 常见的副作用包括:恶心 (46.9%),头痛 (18.4%),吐 (14.3%).
- 主题建模揭示了食欲抑制,成本和获取的主题.
结论:
- 人工智能和NLP有效地分析患者报告的数据,以确定西马格卢提德的现实世界概况.
- 研究结果支持将患者报告的结果纳入营销后监测.
- 这种分析有助于在体重管理方面的治疗决策.
相关概念视频
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248

